Intent on slowing or stopping the progression of Alzheimer’s
Satori Pharmaceuticals is developing life-changing therapeutics for
Alzheimer's disease (AD). The Company is led by a seasoned management team with
deep CNS drug discovery and development experience. Combined, the team has
helped develop over 100 clinical candidates and more than 10 approved drugs.
This substantial experience bringing novel medicines to patients enables the
management team to employ a top of industry approach to the development of its
drug candidates – utilizing clinical strategies that are familiar to
pharmaceutical companies working in AD.
The internal team is supported by a world-class team of scientific advisors,
made up of many of the industry's leading experts on AD, an experienced Board
of Directors with a range of industry backgrounds and a stellar group of life
science investors with a long track record of nurturing important new medicines
to the market.